Characterization of a Novel Human Serine Protease That Has Extensive Homology to Bacterial Heat Shock Endoprotease HtrA and Is Regulated by Kidney Ischemia*

(Received for publication, July 15, 1999, and in revised form, October 22, 1999)

Lucia Facciò, Carlo Fusco, Ang Chen, Stefano Martinotti, Joseph V. Bonventre, and Antonis S. Zervos

From the Cutaneous Biology Research Center, Massachusetts General Hospital/Harvard Medical School, the Renal Unit, Medical Services, Massachusetts General Hospital and Department of Medicine, Harvard Medical School, Charlestown, Massachusetts 02129, and the Department of Experimental Medicine, University of L'Aquila, L'Aquila 67100, Italy

We report the isolation and characterization of a cDNA encoding the novel mammalian serine protease Omi. Omi protein consists of 458 amino acids and has homology to bacterial HtrA endoprotease, which acts as a chaperone at low temperatures and as a proteolytic enzyme that removes denatured or damaged substrates at elevated temperatures. The carboxyl terminus of Omi has extensive homology to a mammalian protein called L56 (human HtrA), but unlike L56, which is secreted, Omi is localized in the endoplasmic reticulum. Omi has several novel putative protein-protein interaction motifs, as well as a PDZ domain and a Src homology 3-binding domain. Omi mRNA is expressed ubiquitously, and the gene is localized on human chromosome 2p12. Omi interacts with Mxi2, an alternatively spliced form of the p38 stress-activated kinase. Omi protein, when made in a heterologous system, shows proteolytic activity against a nonspecific substrate β-casein. The proteolytic activity of Omi is markedly up-regulated in the mouse kidney following ischemia/reperfusion.

Mammalian cells are often exposed to adverse environmental conditions brought about by changes in temperature, pH, infections by bacteria and viruses, reactive oxygen species, toxins, or ischemia/reperfusion. Some of these stress conditions can result in the accumulation of damaged and/or denatured proteins within cells. Spontaneous mutations can also cause misfolding of a particular polypeptide. To monitor and assist the proper folding of proteins, cells have numerous specialized proteins, including chaperones and proteases. Accumulation of misfolded proteins in the endoplasmic reticulum (ER) leads to the activation of the unfolded protein response (1), an intracellular pathway present in all eukaryotic cells that originates in the ER. When activated, the unfolded protein response controls the transcription of genes involved in protein folding (2). This results in the proper folding or removal of damaged proteins in the ER, which is necessary for the recovery and ultimate survival of cells following environmental stress. In bacteria exposed to elevated temperature or oxidative stress, damaged and denatured proteins are removed by the action of the HtrA (high temperature requirement A) endoprotease (reviewed in Ref. 3). HtrA is localized in the periplasmic space of bacteria, and its presence is necessary for bacterial thermostolerance. HtrA is an active serine protease and has two PDZ domains known to be involved in protein-protein interactions (4–6). It has recently been found that bacterial HtrA has a dual role acting as chaperone at normal temperatures and an active protease at elevated temperatures (7). Here we report the isolation and characterization of a mammalian homologue of HtrA, which we call Omi. Omi is a novel serine protease that has extensive homology to the bacterial HtrA heat shock protease. Omi also has homology with L56, a cDNA isolated in a differential screen for mRNAs repressed by SV40 transformation of human fibroblasts (8). The L56 cDNA (human HtrA) was also independently isolated as a differentially expressed protein in human osteoarthritic cartilage (9). The homology among Omi, L56, and HtrA is restricted to the carboxyl terminus of the polypeptides; the amino terminus for each protein is unique. Furthermore, Omi is immunolocalized exclusively in the ER, whereas L56 is secreted. Omi has numerous protein-protein interaction motifs, including a SH3-binding domain, a novel motif that is repeated three times in Omi, a PDZ domain, and a putative transmembrane region. Via its PDZ domain, Omi can specifically bind the carboxyl terminus of Mxi2, an alternatively spliced form of p38 stress-activated kinase (10). Baculovirus-expressed Omi shows proteolytic activity in an assay that uses β-casein as a generic substrate. We used a mouse model system of kidney ischemia/reperfusion to investigate whether the proteolytic activity of Omi is regulated by stress. The same model system has been extensively used to study regulation of stress-activated kinases (11, 12) or heat shock proteins, such as heat shock protein 70 (13). In this model, the proteolytic activity of Omi was substantially increased following kidney ischemia/reperfusion. This suggests activation of Omi may play a role in the biochemical changes that follow kidney ischemia and may serve as a cellular protective response.

Experimental Procedures

Isolation of Omi—A HeLa cDNA library was screened using a modified yeast two-hybrid system (14, 15). We used the full-length Mxi2 fused to LexA1–220 as a bait. EGY48 (MATalphaura3his3leu2::p3LexAop-Leu2) yeast strain was used, which has an integrated...
LEU reporter gene and upstream LexA operators as well as a pβH18–34 (LexAop-lacZ) 2 µ plasmid that directs the synthesis of β-galactosidase (14). Of the 1 million primary yeast colonies screened, 88 colonies were initially isolated by their ability to grow on Gal-Ura-His-Trp-Leu-selective plates. When these were tested on Ura-His-Trp-X-gal plates, 5-AAG GGC TGC TGT GCC TAT CAT AAC CAA AGC TTC AAT-3

9

made using the following primers: sense primer Mxi2 primer p38, 5'-Mxi and the antisense primer p38. The final PCR product encoding 1 antisense primer Mxi2, 5'-GGG ACC TCC

AGA GGC CC-3'. The following primers were used to subject to PCR a DNA fragment encoding the PDZ domain of Omi corresponding to amino acids 1480–1486: L56 PDZ 5' end, 5'-GAT GTG CAT GGA TAT GCC TCT CCC GAA TTC CAC AAG TTC CAG TTT CCC GAT GTT-3'; 3' end, 5'-CTG CGG AAG AAT CCA AAC CTT CAT GTC ATG CTA GCC GGG TCA-3'. The PCR products were cloned into the yeast vector pMuG4–5 vector (14) by homologous recombination as described in Ref. 17. Expression of these proteins was confirmed by Western blot analysis of yeast extracts using anti-HA antibody. Interaction of these fusion proteins with Mxi2 in yeast was detected using standard procedures (15).

Northern Blot Analysis—Human mRNA tissue and cancer blot (CLONTECH) were hybridized at 42 °C with a radiolabeled probe corresponding to full-length Omi cDNA, as described previously (18). Blots were washed at 65 °C with 2% SSC, 0.1% SDS for 10 min followed by 0.1% SSC, 0.1% SDS for 30 min. The blots were then subjected to autoradiography.

Preparation of Omi Polyclonal Antibody—Anti-Omi antibodies were prepared by immunizing rabbits with the carboxyl-terminal region of Omi protein (residues 217–458) fused to the maltose-binding protein (New England Biolabs). The fusion protein was expressed in E. coli and purified using maltose-amylose resin (New England Biolabs). Affinity purified maltose-binding protein-Omi was resolved on polyacrylamide gels. Acrylamide gel pieces containing the maltose-binding protein-Omi fusion protein were excised and used to inject rabbits (Cocalico Biologicals, Inc). Anti-Omi antibodies were affinity purified on a column of maltose-binding-protein-Omi covalently linked to Sepharose. Immunoblotting was performed using the anti-Omi antiseraum at 1:1000 dilution. The secondary antibody used was a goat anti-rabbit horseradish peroxidase conjugate (Bio-Rad). Visualization of antibody binding was carried out using the ECL detection system (Amersham Pharmacia Biotech).

Production of Recombinant Baculovirus—The DNA coding for the full-length Omi was subcloned into the pAcGHTL (Pharmingen) vector, downstream of the coding sequence of glutathione S-transferase (GST). In order to make the OmiS306A mutant, a four-nt, two-reaction protocol was used. Briefly, two overlapping PCR fragments were generated incorporating the codon change for the new amino acid. The primers used for the first set of reactions were as follows: sense primer A, 5'-CCG CAA TTG ATG GCG CCG CAG GGC-3'; antisense primer B, 5'-GGG ACC TCC GCC GGT TTC C-3'. The primers used for the second set of reactions were as follows: sense primer C, 5'-TTT GGA AAC GCC GGA GGT C-3'; antisense primer D, 5'-GGG GTA CCT CAT TCT GTG ACC TCA GG-3'. The final PCR was performed using sense primer A and antisense primer D and the PCR products from the previous reactions as template. The final 1.370-kb DNA fragment encoding the mutant OmiS306A was digested with MfeI/KpnI and cloned into the EcoRI/KpnI sites of the pAcGHTL expression vector. The construction of both the wild-type and OmiS306A mutant Omi was confirmed by DNA sequencing of both strands (United States Biochemicals). SF9 insect cells were co-transfected with the recombinant transfer vector and linearized BaculoGold baculovirus DNA (Pharmingen), according to the manufacturer's instructions. A high titer solution of recombinant baculovirus was used to infect SF9 cells. After 3 days of incubation at 27 °C, the insect cells were removed from the culture plates and recovered by low speed centrifugation. The cell pellets were stored at −80 °C until further processing.

Purification of Omi-GST Fusion Protein—Infected SF9 cells were resuspended into cell lysis buffer (Pharmingen) without protease inhibitors, using 1 ml of buffer for 2 x 10^6 cells. Cell lysis was performed on ice for 45 min and completed by Dounce homogenization. The cell lysate was clarified by low speed centrifugation at 40,000 x g for 45 min. The supernatant was then added to glutathione-conjugated Sepharose beads (Sigma), and the slurry was incubated for 30 min at 4 °C on a rotating platform. The beads were recovered by low speed centrifugation and washed twice with a large excess of cold washing buffer solution (8 mM sodium phosphate buffer, pH 7.3, 1 mM EDTA, 150 mM sodium chloride) (1%). Following by three washes with 50 mM Tris-HCl, pH 7.6, the bound material was then eluted twice (20 min at room temperature) with 5 mM reduced glutathione in 50 mM Tris-HCl, pH 7.6, using a volume of reduced glutathione equal to the initial volume of packed beads. The presence of GST-Omi fusion protein was confirmed by immunoblot analysis using anti-Omi antiseraum. The purified protein was used for proteolytic assays at a concentration of approximately 1 mg/ml.
Isolation and Sequence Characterization of Omi cDNA—In order to isolate Mxi2-interacting proteins, we used a modified yeast two-hybrid system to screen a HeLa cDNA library (14, 15). Of the 10⁶ primary yeast transformants screened, 88 colonies appeared to contain a potential interactor. Of these, only two had an unambiguous phenotype. The two plasmids were rescued and shown to represent the same cDNA, although one had a longer 3′ untranslated sequence (results not shown). The partial cDNA encoded a polypeptide of 312 amino acids fused in-frame to the B42 activation domain of the pJG-4.5 vector. Sure-RACE PCR (Origene) was used to obtain the complete 5′ Omi cDNA sequence. Sequence (GNSGGGPL) surrounding the active site of the catalytic domain with similarity to the consensus sequence of trypsin-like serine proteases is in boldface; the His, Asp, and Ser (catalytic triad) amino acids required for proteolytic activity are circled and in boldface; the SH3-binding sequence and the PRAXXXXTP motifs are boxed. The putative transmembrane region is double underlined, and the PDZ domain is underlined. B, schematic diagram of the domain structure of Omi. There is a catalytic domain (CD) localized at the carboxy terminus of the protein with homology to serine proteases. Adjacent to the catalytic domain, there is a PDZ domain. The amino terminus of Omi contains the regulatory domain (RD) with unique sequence that includes three copies of a sequence motif (PRAXXXTP), a putative transmembrane domain (TM), and an SH3-binding motif (PPPSPR).

**Assays for the Proteolytic Activity of Omi**—The proteolytic activity of Omi was measured using a commercially available assay system (Athena Environmental Sciences, Inc.). The assay employs a universal substrate of a dye-protein conjugate cross-linked to a matrix. Protease activity is determined spectrophotometrically by measuring the absorbance of the dye released from the matrix to the supernatant. The assay employs a universal substrate of a dye-protein conjugate cross linked to a matrix. Protease activity is determined spectrophotometrically by measuring the absorbance of the dye released from the matrix to the supernatant. The activity of Omi was measured at different incubation times, and reactions were terminated by adding 500 µl of 0.2 N NaOH to each vial. The absorbance of the supernatant in each reaction vial was measured at 450 nm. The proteolytic activity of baculovirus made GST-Omi fusion was monitored using 10 µl (approximately 10 µg) of purified protein incubated with 5 µg of β-casein (Sigma) in 50 mM Tris-HCl (pH 7.5) for 30 min, 1 h or 2 h at 37°C. The proteolytic activity of GST-OmiS306A was monitored using 20 µg of purified protein incubated with 5 µg of β-casein (Sigma) in 50 mM Tris-HCl (pH 7.5) for 3 h. The reaction products were resolved by SDS-polyacrylamide gel electrophoresis and proteins visualized by staining with Coomassie Blue.

**Immunocytochemistry**—COS-7 cells were plated at 80% confluency on culture dishes (100 mg/µl)-coated coverslips. Cells were rinsed with PBS and fixed with 3.7% paraformaldehyde containing 0.1% Tween-20 in PBS at room temperature for 10 min. Incubation with primary and secondary antibodies was performed at room temperature for 1 h, followed by three 15-min washes in PBS. The following primary antibodies were used: rabbit polyclonal against Omi at a concentration of 0.8 µg/ml and mouse monoclonal antibody against BIP (StressGen) used as an ER-specific marker at a dilution of 1:500. The secondary antibodies were fluorescein-conjugated anti-rabbit IgG (SantaCruz), used at a concentration of 15 µg/ml, and rhodamine-conjugated anti-mouse IgG (Cappel), used at a dilution of 1:100.

**Mouse Kidney Ischemia/Reperfusion**—The left kidney of Balb/c mice was removed through a flank incision as described previously (19). Twenty-four h later, ischemia of the right kidney was induced for 30 min followed by reperfusion (19). Kidneys were harvested 1 or 24 h after reperfusion. The mouse kidneys were homogenized in 5 ml of lysis buffer (20 mM Hepes, pH 7.4, 2 mM EGTA, 1 mM dithiothreitol, 1× Trasylol, 50 mM β-glycerophosphate) and sonicated on ice. Lysates were centrifuged for 10 min at 3000 rpm at 4°C, and the collected supernatants were further centrifuged for 1 h at 100,000×g. The kidney supernatant was kept in a final concentration of 1% Triton X-100 and 1 mM Na3VO4. 150 µg of total protein extracts was separated on an SDS-polyacrylamide gel, and the amount of Omi protein was detected by Western blot analysis using the Omi polyclonal antibody (1:1000).

**RESULTS**

**Isolation of Omi, a Human HtrA Homologue**—The original cDNA clone isolated in the two-hybrid screen encoded 312 residues, corresponding to amino acids 147–458, shown here. Sure-RACE PCR (Origene) was used to obtain the complete 5′ Omi cDNA sequence. Sequence (GNSGGGPL) surrounding the active site of the catalytic domain with similarity to the consensus sequence of trypsin-like serine proteases is in boldface; the His, Asp, and Ser (catalytic triad) amino acids required for proteolytic activity are circled and in boldface; the SH3-binding sequence and the PRAXXXXTP motifs are boxed. The putative transmembrane region is double underlined, and the PDZ domain is underlined. B, schematic diagram of the domain structure of Omi. There is a catalytic domain (CD) localized at the carboxy terminus of the protein with homology to serine proteases. Adjacent to the catalytic domain, there is a PDZ domain. The amino terminus of Omi contains the regulatory domain (RD) with unique sequence that includes three copies of a sequence motif (PRAXXXXTP), a putative transmembrane domain (TM), and an SH3-binding motif (PPPSPR).

**Assays for the Proteolytic Activity of Omi**—The proteolytic activity of Omi was measured using a commercially available assay system (Athena Environmental Sciences, Inc.). The assay employs a universal substrate of a dye-protein conjugate cross linked to a matrix. Protease activity is determined spectrophotometrically by measuring the absorbance of the dye released from the matrix to the supernatant. The assay employs a universal substrate of a dye-protein conjugate cross linked to a matrix. Protease activity is determined spectrophotometrically by measuring the absorbance of the dye released from the matrix to the supernatant. The activity of Omi was measured at different incubation times, and reactions were terminated by adding 500 µl of 0.2 N NaOH to each vial. The absorbance of the supernatant in each reaction vial was measured at 450 nm. The proteolytic activity of baculovirus made GST-Omi fusion was monitored using 10 µl (approximately 10 µg) of purified protein incubated with 5 µg of β-casein (Sigma) in 50 mM Tris-HCl (pH 7.5) for 30 min, 1 h or 2 h at 37°C. The proteolytic activity of GST-OmiS306A was monitored using 20 µg of purified protein incubated with 5 µg of β-casein (Sigma) in 50 mM Tris-HCl (pH 7.5) for 3 h. The reaction products were resolved by SDS-polyacrylamide gel electrophoresis and proteins visualized by staining with Coomassie Blue.

**Immunocytochemistry**—COS-7 cells were plated at 80% confluency on culture dishes (100 mg/µl)-coated coverslips. Cells were rinsed with PBS and fixed with 3.7% paraformaldehyde containing 0.1% Tween-20 in PBS at room temperature for 10 min. Incubation with primary and secondary antibodies was performed at room temperature for 1 h, followed by three 15-min washes in PBS. The following primary antibodies were used: rabbit polyclonal against Omi at a concentration of 0.8 µg/ml and mouse monoclonal antibody against BIP (StressGen) used as an ER-specific marker at a dilution of 1:500. The secondary antibodies were fluorescein-conjugated anti-rabbit IgG (SantaCruz), used at a concentration of 15 µg/ml, and rhodamine-conjugated anti-mouse IgG (Cappel), used at a dilution of 1:100.

**Mouse Kidney Ischemia/Reperfusion**—The left kidney of Balb/c mice was removed through a flank incision as described previously (19). Twenty-four h later, ischemia of the right kidney was induced for 30 min followed by reperfusion (19). Kidneys were harvested 1 or 24 h after reperfusion. The mouse kidneys were homogenized in 5 ml of lysis buffer (20 mM Hepes, pH 7.4, 2 mM EGTA, 1 mM dithiothreitol, 1× Trasylol, 50 mM β-glycerophosphate) and sonicated on ice. Lysates were centrifuged for 10 min at 3000 rpm at 4°C, and the collected supernatants were further centrifuged for 1 h at 100,000×g. The kidney supernatant was kept in a final concentration of 1% Triton X-100 and 1 mM Na3VO4. 150 µg of total protein extracts was separated on an SDS-polyacrylamide gel, and the amount of Omi protein was detected by Western blot analysis using the Omi polyclonal antibody (1:1000).

**RESULTS**
in the regulatory domain (Fig. 1B). This was the first report on the identification of this motif. No function associated with this structure has been reported thus far.

The catalytic domain of Omi showed extensive homology to *E. coli* heat shock protease HtrA as well as with a mammalian protein called L56/hHtrA (8, 9) (Fig. 2). The catalytic domain of Omi had 51% identity and 68% similarity with the corresponding domain of L56/hHtrA and 36% identity and 58% similarity with bacterial HtrA. Like L56/hHtrA, Omi also has a single PDZ domain whereas the bacterial HtrA has two PDZ domains. These PDZ domains are involved in binding directly to the carboxyl termini of target proteins (6).

**In Vivo Association of Omi with Mxi2**—To study the interaction of Mxi2 or p38 and Omi in vivo, we performed co-immunoprecipitation experiments using HEK293 cells transiently transfected with plasmids expressing Mxi2-HA or p38-HA. We used a polyclonal antibody raised against Omi to precipitate the endogenous protein. After resolving the precipitated complex on an SDS-polyacrylamide gel, the presence of HA-Mxi2 or HA-p38 in the complex was detected using anti-HA antibody. These experiments showed that Omi can bind Mxi2 in vivo, and that the affinity of the interaction is strong enough to allow the proteins to co-immunoprecipitate. Omi was able to interact with Mxi2 when the transfected cells were treated with anisomycin (an activator of p38 stress-activated kinases) or SB205380 (a known inhibitor of p38 kinase). In the same experiment, no interaction was detected between HA-p38 and Omi (Fig. 3A).

**Mapping Interaction Domain of Mxi2/Omi**—To define the amino acid sequence of Mxi2 responsible for binding to Omi, LexA-fusions corresponding to the full-length Mxi2 (aa 1–297) and three deletion mutants of Mxi2 (ΔMxi2 aa 1–295, ΔMxi2 aa 1–293, and ΔMxi2 aa 1–291) were made. Also, full-length LexA-p38 (aa 1–360) and two chimeric fusion proteins, one containing the p38-specific carboxyl-terminal domain (PSD) fused to LexA-Mxi2 (LexA-Mxi2 PSD) and another containing the Mxi2-specific carboxyl-terminal domain (MSD) fused to p38 (LexA-p38 MSD), were used (Fig. 3B). In these experiments, Mxi2 but not p38 was able to bind to Omi and the carboxyl-terminal sequence of Mxi2 was required for interaction. Deletion of the last amino acid of Mxi2 abolished most of the binding with Omi (Fig. 3B). When the carboxyl terminus of Mxi2 was blocked by fusing the p38-specific, 80-amino acid sequence, the interaction with Omi was abolished. This indicated that the recognition sequence has to be at the end of the carboxyl terminus of the protein. To further explore the properties of the unique sequence of the carboxyl terminus of Mxi2, the 17-amino acid long Mxi2-specific carboxyl terminus was fused to the end of p38 and the interaction between Mxi2 and the PDZ domain of Omi was highly specific. Mxi2 was not able to interact with the PDZ domain of L56, a homologue of Omi that has a PDZ domain with high similarity to the PDZ domain of Omi (see Fig. 2).

**Expression of Omi mRNA in Normal Human Tissues and Transformed Cell Lines, and Chromosomal Localization**—To investigate the expression of Omi, we performed Northern blot analysis using mRNA from different human tissues as well as
from a number of tumor cell lines. As shown in Fig. 4, Omi is represented by two distinct mRNA species that are expressed ubiquitously, a major one of approximately 2.1 kb and a minor one of 4.5 kb. The highest level of Omi expression is found in placenta and pancreas (Fig. 4A). In tumor cell lines, high expression of Omi was found in promyelocytic leukemia HL-60, chronic myelogenous leukemia K-562, Burkitt lymphoma Raji, and human colorectal carcinoma SW480 cell lines (Fig. 4B). The Omi gene is localized on human chromosome 2, region p12 (Fig. 5). Translocations and deletions of this region are found in acute and chronic lymphocytic leukemias, as well as nonlymphocytic leukemia and Hodgkin disease (22).

Omi Localizes to the ER—Fig. 6 shows a fluorescent micrograph of COS-7 cells stained with anti-Omi antibody. The fluorescence distribution, a fine reticular network all over the cytoplasm and around the nuclear envelope, was suggestive of an ER staining pattern. To confirm that the endogenous Omi protein is localized in the ER, we compared the fluorescence staining pattern of cells stained with Omi antibodies and BiP staining. BiP is a well characterized marker localized in the ER-lumen. The two staining patterns were almost identical, indicating that Omi is localized predominantly in the ER.

Omi Has Proteolytic Activity—The Omi cDNA representing the entire coding sequence was cloned into pAcGHTL baculovirus vector (Pharmingen) that expresses the Omi protein as a fusion to the GST. Expression of the fusion protein was detected by immunoblot analysis using anti-Omi antiserum and the protein was purified on a GST column (Amersham Pharmacia Biotech). Fig. 7A shows the proteolytic activity of the purified GST-Omi protein. The GST-Omi protein was concentrated and incubated for varying lengths of time with β-casein at 37 °C. Proteolytic activity was detected as early as 30 min (Fig. 7A, lane c), and the substrate used in the assay was completely degraded after 2 h (lane e). The baculovirus GST-Omi (S306A) mutant, which changes serine 306 to an alanine (S306A), showed no detectable protease activity after 3 h incubation (Fig. 7B).

Proteolytic Activity of Omi Is Regulated during Kidney Ischemia/Reperfusion—Using Omi-specific antibodies, the protein was precipitated from kidney extracts of mice that underwent ischemia and reperfusion as described under "Experimental Procedures." The proteolytic activity of Omi was monitored using a commercially available protease assay kit (Athena Environmental Sciences, Inc.). The results of these experiments are shown in Fig. 8. Omi isolated from control mouse kidneys had inherently weak protease activity. This proteolytic activity of Omi dramatically increased after ischemia/reperfusion. In these experiments the proteolytic activity was normalized to the amount of Omi protein. Western blot analysis of mouse kidney extracts identified Omi as a single polypeptide band with a molecular mass of 50 kDa. Furthermore, the level of Omi protein in the mouse kidneys did not change after ischemia/reperfusion when compared with controls (Fig. 8B).

**DISCUSSION**

We describe the isolation and characterization of Omi, a human homologue of the bacterial HtrA endoprotease. Prokaryotic heat shock proteins (HtrAs) are enzymes activated by high temperature that remove denatured or damaged proteins from heat-stressed bacteria (23–26). The importance of HtrAs...
became apparent when it was learned that bacteria lacking this enzyme are unable to survive at 42 °C (24, 26). Furthermore, pathogenic bacteria that lack HtrA are less virulent, suggesting that Omi may have a role in counteracting and neutralizing host bactericidal mechanisms (3). Recently, it has been reported that bacterial HtrA has a dual role, acting as a chaperone at normal temperatures and as an active protease against a natural substrate (the MalS protein) at elevated temperatures (7). The homology of HtrA and Omi is quite substantial and extends across the full length of the catalytic domain. Extensive search of the GenBank™ identified one more mammalian protein, L56, that has substantial homology to Omi and HtrA. L56 was isolated in a screen to identify differentially expressed genes when cells are transformed by SV40 virus (8). L56 is expressed in normal human fibroblasts, but its expression is inhibited when the same fibroblasts are infected with SV40 (8). The homology of L56 with Omi extends in the catalytic domain at the carboxyl termini of the proteins, and no homology is found in the regulatory domain present at the amino termini. L56 protein is secreted (9) whereas Omi is found in the ER. The different subcellular localization of Omi and L56 and their unique regulatory domains present at their amino termini suggest distinct functions for these two proteins. The proteolytic activity of E. coli HtrA, as well as that of L56 (human HtrA), has been shown to be completely eliminated by mutating the serine in the catalytic domain (GNSGGA) or the histidine in position 105 (27). The serine at position 306 is an invariant amino acid in the “catalytic triad” of His, Ser, and Asp residues found in the catalytic domain of several serine proteases. When we made Omi in a baculovirus system that also has the serine in position 306 mutated to an alanine (S306A), this mutant Omi had no detectable protease activity against β-casein.

The amino terminus of Omi has a PPPASPR sequence that is identified as a SH3-binding domain (20, 21). It also has three copies of the sequence motif PRAXXXTXXTP, where X is any amino acid. This sequence has not been reported before, and its function is unknown. We assume that the unique amino-terminal regulatory domain of Omi is involved in protein-protein interactions. Omi also has a PDZ domain at its carboxyl terminus. PDZ domains are named after the three...
proteins in which they were first identified: postsynaptic density protein-95 (PSD-95) (28); Drosophila discs large tumor suppressor (Dlg) (29), and the tight junction protein, (ZO-1) (30). The PDZ domain of Omi specifically recognizes the carboxyl terminus of Mxi2 and is responsible for its interaction with this kinase.

FIG. 6. Subcellular localization of Omi in COS-7 cells. Fluorescence images of COS-7 cells expressing endogenous Omi stained with the purified polyclonal Omi antibody followed by fluorescein-conjugated anti-rabbit IgG (A). The same cells were also stained with a mouse monoclonal antibody against the ER-resident protein (BiP) followed by rhodamine-conjugated anti-mouse IgG (B). C, merged images of A and B showing co-localization of Omi with the ER-resident protein BiP.

FIG. 7. GST-Omi protein expressed in baculovirus-infected SF9 cells is an active protease. A, Coomassie Blue-stained acrylamide gel of GST-Omi incubated at different times with β-casein. All incubations were performed at 37 °C. Lane a, GST-Omi, 2-h incubation; lane b, β-casein, 2-h incubation; lane c, GST-Omi + β-casein, 30-min incubation; lane d, GST-Omi + β-casein, 1-h incubation; lane e, GST-Omi + β-casein, 2-h incubation. Reactions were terminated by adding SDS-sample buffer, and proteins were resolved on a polyacrylamide gel and stained with Coomassie Blue. The bracket indicates the position of the intact GST-Omi; the arrow indicates the position of the β-casein substrate. B, Coomassie Blue staining of GST-OmiS306A incubated with β-casein. All incubations were performed at 37 °C. Lane a, β-casein alone, 3-h incubation; lane b, GST-Omi, 3-h incubation; lane c, GST-OmiS306A, 3-h incubation.

FIG. 8. Protease activity of Omi is regulated during kidney ischemia/reperfusion. A, Omi was precipitated from kidney extracts of control or ischemic mice, and the protease activity monitored using a commercially available kit. Activity is shown as the absorbance at 450 nm of substrate released. The activity shown is the average of three independent measurements using two mice for each measurement. Two independent experiments performed with mice are shown here, at 1 and 24 h following kidney ischemia/reperfusion. B, equal amounts of protein extracts from mouse kidneys that underwent ischemia/reperfusion (I) for 1 or 24 h or control (C) were resolved by SDS-polyacrylamide gel electrophoresis and analyzed by Western blot using Omi antibodies.
Omi mRNA is expressed ubiquitously, and increased levels were found in several tumor cell lines. Omi is localized on human chromosome 2p12 at a region reported to be rearranged in several human leukemias (22). Whether Omi overexpression plays a role in the development or progression of human cancer is not known. Because Omi might be involved in the cellular response to stress, its overexpression may render transformed cells more resistant to cellular damage caused by extracellular stress, hyperthermia, or chemotherapeutic agents.

To investigate any potential role of Omi in cellular stress, we used a mouse model system of kidney ischemia/reperfusion (19). Proteases, such as calpain (31) and caspases (32), have been found to be increased in activity and have been implicated in the pathophysiology of ischemic injury to the kidney and other organs. In the brain, for example, inhibition of calpain-mediated proteolysis protects hippocampal neurons against ischemic injury (33). We are proposing, however, that Omi may act similarly to heat shock proteins, which have been implicated in the protection of the kidney and other organs against ischemic injury (34).

We found that although the levels of Omi protein remained the same, the proteolytic activity of the enzyme substantially increased after ischemia/reperfusion. This suggests that the activity of Omi may be regulated by a post-translational mechanism such as phosphorylation. Alternatively, the protease activity of Omi might be regulated through protein-protein interactions at its amino-terminal regulatory domain. Whether this increase in the activity of Omi is necessary for the cellular changes that follow kidney damage and recovery remains to be investigated. Omi has numerous protein-protein interaction motifs that could target specific substrates for degradation after these proteins are denatured or damaged following stress. Alternatively, Omi could act as a chaperone to assist the proper folding and renaturation of substrates that bind to its numerous protein-protein interaction domains. The exclusive localization of Omi in the ER further reinforces the suggestion that its function could be to assist the proper folding of proteins and/or to degrade and remove damaged polypeptides. Whether Omi is a new member of the unfolded protein response pathway that originates in the ER and regulates the transcription of several target genes involved in protein folding remains to be elucidated. The presence of specific protein-protein interaction motifs at the amino terminus of Omi further suggests the proteolytic activity of Omi may be targeted to specific substrates. Isolation and characterization of these substrates will assist the elucidation of the physiological function of Omi and its potential role in stress.

Acknowledgments—We are grateful to A. Alessandrini for comments, suggestions, and critical reading of the manuscript and to A. Viel for the synthesis and purification of baculovirus GST-Omi. We especially thank R. Crowl for sharing information and for the L56/hHtra cDNA.

REFERENCES
1. Sidrauski, C., Chapman, R., and Walter, P. (1998) Trends Cell Biol. 8, 245–249
2. Chapman, R., Sidrauski, C., and Walter, P. (1998) Annu. Rev. Cell Dev. Biol. 14, 459–485
3. Pallen, M. J., and Wren, B. W. (1997) Mol. Microbiol. 26, 209–221
4. Fanning, A. S., and Andersen, J. M. (1996) Curr. Biol. 6, 1385–1388
5. Harrison, S. C. (1996) Cell 86, 341–343
6. Saraf, J., and Heldin, C. H. (1996) Trends Biochem. Sci. 21, 455–458
7. Spiess, C., Beil, A., and Ehrmann, M. (1999) Cell 97, 339–347
8. Zumbrunn, J., and Trueb, B. (1996) FEBS Lett. 389, 187–192
9. Hu, S.-I., Carozza, M., Klein, M., Nantemnet, P., Luk, D., and Crowl, R. M. (1998) J. Biol. Chem. 273, 34406–34412
10. Zervas, A. S., Faccio, L., Gatto, J., Kyrriakis, J. M., and Brent, R. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 10531–10534
11. De Silvia, H., Cioffi, C., Yin, T., Sandhu, G., Webb, R. L., and Whelan, J. (1998) Biochem. Biophys. Res. Commun. 250, 647–652
12. Safirstein, R. (1997) Adv. Renal Replace. Ther. 4, 38–42
13. Lovis, C., Mach, F., Denati, Y. R., Bonventre, J. V., and Polli, B. S. (1994) Renal Failure 16, 179–192
14. Gyuris, J., Golemis, E., Chertkov, H., and Brent, R. (1993) Cell 75, 791–803
15. Zervas, A. S., Gyuris, J., and Brent, R. (1993) Cell 72, 223–232
16. Pear, W. S., Nolan, G. P., Scott, M. L., and Baltimore, D. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 8392–8396
17. Fusco, C., Guidotti, E., and Zervas, A. S. (1999) Yeast 15, 715–720
18. Eo, J., and Zervas, A. S. (1998) Oncogene 12, 2171–2176
19. Ouellette, A. J., Malt, R. A., Sukhatme, V. P., and Bonventre, J. V. (1990) J. Clin. Invest. 85, 766–771
20. Cohen, G. B., Ben, R., and Baltimore, D. (1995) Cell 86, 237–248
21. Koch, C. A., Anderson, D., Moran, M. F., Ellis, C., and Pawson, T. (1991) Science 252, 668–674
22. Shapiro, D. N., Valentine, V., Eagle, L., Yin, X., Morris, S. W., and Prochownik, E. V. (1994) Genomics 23, 282–285
23. Lipinska, B., Sharma, S., and Georgopoulos, C. (1988) Nucleic Acids Res. 16, 10653–10667
24. Lipinska, B., Fuyet, O., Baird, L., and Georgopoulos, C. (1989) J. Bacteriol. 171, 1574–1584
25. Lipinska, B., Zyliez, M., and Georgopoulos, C. (1990) J. Bacteriol. 172, 1789–1797
26. Strauch, K., Johnson, K., and Beckwith, J. (1989) J. Bacteriol. 171, 2689–2696
27. Skorko-Glonek, J., Krzewski, K., Lipinska, B., Bertoli, E., and Tafani, F. (1995) J. Biol. Chem. 270, 11110–11116
28. Cho, K. O., Hunt, C. A., and Kennedy, M. B. (1992) Neuron 9, 929–942
29. Woods, D. F., and Bryant, P. J. (1991) Cell 66, 451–464
30. Itoh, M., Nagafuchi, A., Yonemura, S., Kitani-Yasuda, T., and Tsukita, S. (1993) J. Cell Biol. 121, 491–502
31. Edelstein, C. L., Ling, H., and Schrier, R. W. (1997) Kidney Int. 51, 1341–1351
32. Kaushal, G. P., Singh, A. B., and Shah, S. V. (1998) Am. J. Physiol. 274, F587–F595
33. Yokota, M., Tani, E., Tsukuba, S., Yamaura, I., Nakagaki, I., Hori, S., and Saido, T. C. (1999) Brain Res. 819, 8–14
34. Molitoris, B. A. (1998) Curr. Opin. Nephrol. Hypertens. 7, 405–406